Medlex Inc, 5941 Optical Ct, San Jose, CA 95138, US

Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in San Jose, CA, specializing in first-in-class immune therapies for patients with solid tumors who have poor responses to PD-1 inhibitors. Their lead asset, OBT076, is an Antibody Drug Conjugate (ADC) currently in Phase 1b clinical development, with a dual mechanism of action that primes the patient's immune system and targets cancer cells directly. With a balanced pipeline of internal and partnered programs, OBT focuses on developing novel immunotherapies, including ADCs and checkpoint regulators. They collaborate with key innovators in oncology, such as Boehringer Ingelheim and Kite, a Gilead company. OBT's OGAP platform, the world's largest cancer-specific membrane protein library, identifies highly tumor-specific antigens for first-in-class ADC, Bispecific T-cell Engager (BITE), and Chimeric Antigen Receptor (CAR) targets.Generated from the website

Oxford Biotherapeutics

Era

Loop Genomics

South Bay Bio LLC